CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 88 enrolled
Drug / intervention
Placebo +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07126717
NCT07126717N/ACompleted

Confirmatory Study on the Acute Effects of Zynamite® S on Cognitive Function and Mood in University Students: a Randomized, Double-blind, Placebo-controlled Crossover Study

Nektium Pharma SL·interventional·Posted Aug 17, 2025·Updated Aug 17, 2025

In Brief

A clinical study evaluating Placebo and Zynamite® S for Cognitive Performance and Mood. Completed, enrolled 88 participants across 1 site.

Detailed Summary

The present study sought to confirm the cognitive and mood benefits of a standardized soluble mango leaf extract, named as Zynamite® S. A placebo or a single dose of the botanical extract (100 mg) was administered and its acute effects on mental function and mood were evaluated before product intake, at 30 min, 3 h, and 5 h post-ingestion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSpain

Timeline

N/ACompletedFinished
2026
First PostedAug 17, 2025
Enrollment StartMay 12, 2025
Primary CompletionJun 2, 2025
Study CompletionJun 9, 2025
TodayJul 2, 2026
Enrollment to primary: 20 daysPosted 11 months ago

Interventions

Placebodietary

Food-grade maltodextrin

Zynamite® Sdietary

Water-soluble mango leaf extract standardized to 60% of mangiferin